Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-α and interleukin-6 in patients with sepsis

Critical Care Medicine

Volumn 27, Issue 9, 1999, Pages 1814-1818

  Oberhoffer, Mathias ^a   Karzai, Waheedullah ^a   Meier Hellmann, Andreas ^a   Bögel , Dirk ^a   Faßbinder, Johannes ^a   Reinhart, Konrad ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Body temperature; C reactive protein; Correlation; Interleukin 6; Leukocyte count; Predictive value; Procalcitonin; Receiver operating characteristic; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BODY TEMPERATURE; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INTENSIVE CARE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY TEMPERATURE; C-REACTIVE PROTEIN; CALCITONIN; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032856189     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199909000-00018     Document Type: Article

References (28)

1. 1. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
2. 2. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
3. 3. Barriere SL, Lowry SF: An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23:376-393
4. 4. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1:355-357
5. 5. Bone RC: Why sepsis trials fail. JAMA 1996; 276:565-566
6. 6. Greenman RL, Schein RM, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-1102
7. 7. Solomkin JS, Hill CS: Design problems in clinical sepsis trials. In: Modulation of the Inflammatory Response in Severe Sepsis. Vol 20. Tellado JM, Forse RA, Solomkin JS (Eds). Basel, Karger, 1995, pp 59-66
8. 8. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
9. 9. Natanson C, Hoffmann WD, Suffredini A, et al: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120: 771-783
10. 10. Assicot M, Gendrel D, Carsi H, et al: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 34:515-518
11. 11. Fisher CJ, Opal SM, Dhainaut JL, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
12. 12. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
13. 13. Agresti A: Categorical Data Analysis. New York, Wiley, 1990
14. 14. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839-843
15. 15. Peduzzi P, Shatney C, Sheagren J, et al: Predictors of bacteremia and Gram-negative bacteremia in patients with sepsis. Arch Intern Med 1992:152:529-535
16. 16. Meisner M, Tschaikowsky K, Palmaers T, et al: Procalcitonin and CRP in septic shock: Inflammatory parameters with different kinetics. Abstr. Intensive Care Med 1996; 22:14
17. 17. Meisner M, Tschaikowsky K, Palmaers T, et al: Procalcitonin und CRP bei Sepsis und Multiorganversagen: Korrelationen zu APACHE II und SOFA-Score? Abstr. Anaesthetist 1996; 45:170
18. 18. Dandona P, Nix D, Wilson MF, et al: Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-1608
19. 19. Bohuon C, Petitjean S, Assicot M: Blood procalcitonin is a new biological marker of the human septic response: New data on the specificity. Abstr. Clin Intensive Care 1994; 5:88
20. 20. Gendrel D, Raymond J, Assicot M, et al: Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997; 24:1240-1242
21. 21. Brunkhorst F, Forycki Z, Wagner J: Procalcitonin immunoreactivity in severe human hock. Abstr. Intensive Care Med 1995; 21:12
22. 22. Raue F, Blind E, Grauer A: PDN-21 (katacalcin) and chromogranin A: Tumor markers for medullary thyroid carcinoma. Henry Ford Hosp Med J 1992; 40:296-298
23. 23. Bretagna XY, Nicholson WE, Pettengill OS, et al: Ectopic production of high molecular weight calcitonin and corticotropin by human small cell carcinoma cells in tissue culture: Evidence for separate precursors. J Clin Endocrinol Metab 1978; 47:1390-1393
24. 24. Gendrel D, Assicot M, Raymond J, et al: Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 1996; 128: 570-573
25. 25. Brunkhorst FM, Heinz U, Forycki ZF: Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med 1998; 24:888-889
26. 26. Gramm HJ, Dollinger P, Beier W: Procalcitonin-ein neuer Marker der inflammatorischen Wirtsantwort: Longitudinalstudien bei Patienten mit Sepsis und Peritonitis. Chir Gastroenterol 1995; 11: 51-54
27. 27. Oberhoffer M, Bögel D, Meier-Hellmann A, et al: Procalcitonin vs immunological markers in infection/inflammation. Abstr. Br J Anaesth 1996; 76:A352
28. 28. Darville T, Girior B, Jacobs R: The systemic inflammatory response syndrome (SIRS): Immunology and potential immunotherapy. Infection 1993; 21:279-290